<DOC>
	<DOCNO>NCT01271309</DOCNO>
	<brief_summary>The present project aim determine whether deficit migration stem cell could implicate failure mount adequate collateralization Myocardial Infarction ( MI ) thereby facilitate development post-ischemic heart failure ( HF ) dissect underlie molecular mechanism . Furthermore , investigator wish determine predictive value stem cell migration assay patient MI .</brief_summary>
	<brief_title>Stem Cell Migratory Activity : Prognostic Marker Myocardial Ischemia</brief_title>
	<detailed_description>MAIN OBJECTIVES OF THE STUDY : Characterization circulate CD133+ stem cell group 170 patient MI ( mean post-MI follow , 6 month ) : - Counting total mononuclear cell FACS analysis CD133 stem cell . - Characterization CD133+ stem cell biology : Migratory assay , image cytoskeleton , angiogenesis test vitro . - Evaluation migratory signalling , specific focus PI3K/Akt/eNOS system . Assessment prognostic value stem cell migration assay . - Relationship cell biology test CD133+ cell change circulate cytokine pro-angiogenic factor MI . - Assessment area risk ECG-synchronized Single Photon Emission Computed Tomography ( gated-SPECT ) subgroup different pattern stem cell migratory test . - Assessment ventricular remodelling ( echocardiography , NMR ) relation pattern stem cell migratory test . EXPECTED RESULTS : Clarification implication stem cell migratory deficit post-ischemic HF . - Identification underlie mechanism - Identification cellular marker prediction patient risk HF . RELEVANCE TO PUBLIC HEALTH : - Introduction biological test early diagnosis post-MI HF - Recognition therapeutic target rescue stem cell migratory liability</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Age &gt; = 18 year Thoracic pain last least 20 min ST change leave B block , present previous ECG . MI confirm elevation troponin I CKMB . Patients Killip II e III LV dysfunction include . Patients report thoracic pain 24 hour prior hospitalization HF symptom resistant therapy Haemoglobin &lt; 10 gr/dl Haemodynamic instability ( systolic pressure &lt; 90 mmHg treatment ) Alterations haematopoiesys Concurrent neoplastic disease No write informed consent condition affect patient 's compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>